p53-independent anti-tumor effects of the nitrogen-containing bisphosphonate zoledronic acid

Cancer Science

Volumn 95, Issue 2, 2004, Pages 186-192

  Kuroda, Junya ^a,b   Kimura, Shinya ^a   Segawa, Hidekazu ^a,c   Sato, Kiyoshi ^a,d   Matsumoto, Seiji ^a,d   Nogawa, Masaki ^a   Yuasa, Takeshi ^a   Kobayashi, Yutaka ^b   Yoshikawa, Toshikazu ^b   Ottmann, Oliver G ^e   Maekawa, Taira ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^d KYOTO UNIVERSITY   (Japan)

^e GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CYCLIN A; CYCLIN B; CYCLIN D3; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE; DAUNORUBICIN; GUANOSINE TRIPHOSPHATASE; NITROGEN; PROTEIN P21; PROTEIN P53; PROTEIN P57; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA CELL; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG MECHANISM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN FUNCTION; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CASPASES; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P57; CYCLINS; DIPHOSPHONATES; ENZYME ACTIVATION; FLOW CYTOMETRY; HCT116 CELLS; HUMANS; IMIDAZOLES; IN SITU NICK-END LABELING; NITROGEN; NUCLEAR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 12144289799     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2004.tb03202.x     Document Type: Article

References (37)

1. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-7.
2. Ritter CA, Arteaga CL. The epidermal growth factor receptor-tyrosine kinase: A promising therapeutic target in solid tumors. Semin Oncol 2003; 30: 3-11.
3. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001; 93: 1062-74.
4. Jagdev SP, Coleman RE, Shipman CM, Rostami-H A, Croucher PI. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: Evidence for synergy with paclitaxel. Br J Cancer 2001; 84: 1126-34.
5. Lee MV, Fong EM, Singer FR, Guenette RS. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 2001; 61: 2602-8.
6. Sebti SM, Hamilton AD. Inhibition of Ras prenylation: A novel approach to cancer chemotherapy. Pharmacol Ther 1997; 74: 103-14.
7. + leukemia activity of imatinib mesylate. Blood 2003; 102: 2229-35.
8. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408: 307-10.
9. Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000; 82: 1459-68.
10. Wattel E, Preudohomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994; 84: 3148-57.
11. Lin X, Ramamurthi K, Mishima M, Kondo A, Christen RD, Howell SB. p53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin. Cancer Res 2001; 61: 1508-16.
12. Kimura S, Maekawa T, Hirakawa K, Murakami A, Abe T. Alterations of cmyc expression by antisense oligodeoxynucleotides enhance the induction of apoptosis in HL-60 cells. Cancer Res 1995; 55: 1379-84.
13. Kogure A, Sakane N, Takakura Y, Umekawa T, Yoshioka K, Noshino H, Yamamoto T, Kawada T, Yoshikawa T, Yoshida T. Effects of caffeine on the uncoupling protein family in obese yellow KK mice. Clin Exp Pharmacol Physiol 2002; 29: 391-4.
14. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989; 342: 705-8.
15. Nishida S, Fujii Y, Yoshioka S, Kikuichi S, Tsubaki M, Irimajiri K. A new bisphosphonate, YM529 induces apoptosis in HL60 cells by decreasing phosphorylation of single survival signal ERK. Life Sci 2003; 73: 2655-64.
16. Cip1/Waf1 by caspases is an early event during DNA damage-induced apoptosis. J Biol Chem 1998; 273: 19207-12.
17. WAF1/CIP1 associated with the cyclin A-cyclin-dependent kinases 2 complex is a prerequisite for apoptosis in SK-HEP-1 cells. J Biol Chem 2000; 275: 30256-63.
18. WAF1/Cip1 in human immature leukemic cells. Eur J Haematol 2000; 65: 221-36.
19. Bezzi M, Hasmim M, Bieler G, Dormond O, Ruegg C. Zoledronate sentitizes endothelial cells to tumor necrosis factor-induced programmed cell death: Evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt. J Biol Chem 2003; 278: 43603-14.
20. York RD, Yao H, Dillon T, Ellig CL, Eckert SP, McCleskey EW, Stork PJS. Rap1 mediates sustained MAP kinase activation induced by nerve growth factor. Nature 1998; 392: 622-6.
21. Blagosklonny MV. P53: An ubiquitous target of anti cancer drugs. Int J Cancer 2002; 98: 161-6.
22. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-67.
23. Riebeling C, Forsea AM, Raisova M, Orfanos CE, Geilen CC. The bisphosphonate pamidronate induces apoptosis in human melanoma cells in vitro. Br J Cancer 2002; 87: 366-71.
24. Lotem J, Sachs L. Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Blood 1993; 82: 1092-6.
25. Wada H, Asada M, Nakazawa S, Itoh H, Kobayashi Y, Inoue T, Fukumuro K, Chan LC, Sugita K, Hanada R, Akuta N, Kobayashi N, Mizotani S. Clonal expansion of p53 mutant cells in leukemia progression in vitro. Leukemia 1994; 8: 53-9.
26. Urasaki Y, Ueda T, Yoshida A, Fukushima T, Takeuchi N, Tsuruo T, Nakamura T. Establishment of a daunorubicin-resistant cell line which shows multi-drug resistance by multifactorial mechanisms. Anticancer Res 1996: 16: 709-14.
27. Olson MF Paterson HF Marshall CJ. Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1. Nature 1998; 394: 295-9.
28. KIP2 expression by p73β. Proc Natl Acad Sci USA 2002; 99: 3529-34.
29. Oya M, Schulz WA. Decreased expression of p57(KIP2) mRNA in human bladder cancer. Br J Cancer 2000; 83: 626-31.
30. KIP2 gene in the promoter region in lymphoid malignancies of B-cell phenotype. Blood 2002; 100: 2572-77.
31. Kip2 on staurosporine-induced apoptosis in HeLa cells. Biochem Biophys Res Commun 2000; 296: 702-9.
32. Hsu S, Bollag WB, Lewis J, Huang Q, Singh B, Sharawy M, Yamamoto T, Schuster G. Green tea polyphenols induce differentiation and proliferation in epidermal keratinocytes. J Pharmacol Exp Ther 2003; 306: 29-34.
33. Oades GM, Senaratne SG, Clarke IA, Kirby RS, Colston KW. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing RAS membrane localization in prostate cancer cells. J Urol 2003; 170: 246-52.
34. Kimura S, Kuroda J, Segawa H, Sato K, Nogawa M. Yuasa T, Ottmann OG, Maekawa T. Anti-proliferative efficacy of the third generation bisphosphonate Zoledronic acid combined with other anti-cancer drugs in leukemic cell lines. Int J Hematol in press.
35. Skerjanec A, Berenson J, Hsu C, Major P, Miller WHJ, Ravera C, Schran H, Seaman J, Waldmeier F. The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varing degrees of renal function. J Clin Pharmacol 2003: 43: 154-62.
36. Center for Drug Evaluation and Research. Approval page. Zometa (zoledronic acid) injection. Pharmacology review(s). Part 2: 84. http://www.fda.gov/cder/foi/nda/2001/21-223-Zometa.htm
37. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991; 88: 2095-105.